Payment overview · 2025
General Payments
$1,694.20
55 reported records · 16 companies
Healthcare provider profile · identity verified
Christopher James Brana, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · OXNARD, CA · NPI 1386096345
Verified facts
What the public records show
CMS Open Payments records show Christopher James Brana, M.D. received $1,694.20 in general payments during 2025 across 55 reported records.
Novo Nordisk Inc accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $427.11 | 25.2% | 19 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $251.11 | 14.8% | 7 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $186.11 | 11.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $162.95 | 9.6% | 6 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $147.26 | 8.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $82.00 | 4.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.03 | 4.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.57 | 4.6% | 3 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $72.19 | 4.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.70 | 2.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $34.17 | 2.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.98 | 1.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$29.32 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.38 | 1.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.08 | 1.5% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$18.24 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,694.20 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $251.11 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $218.21 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $162.95 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $131.29 | 5 | 2025 |
Source payment records
|
|||||
| Artis Q floor Normalized: artis q floor |
Device | Siemens Medical Solutions USA, Inc. | $123.61 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $97.41 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $82.00 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $82.00 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $77.57 | 3 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $72.19 | 3 | 2025 |
Source payment records
|
|||||
| MAGNETOM Altea Normalized: magnetom altea |
Device | Siemens Medical Solutions USA, Inc. | $62.50 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.97 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $42.70 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $34.17 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $31.98 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $29.32 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $26.08 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $26.06 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $26.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 47 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 329 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 96 |
| Metformin Hcl | Metformin Hcl | 272 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 204 | 61 |
| Lisinopril | Lisinopril | 190 | 62 |
| Losartan Potassium | Losartan Potassium | 179 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 47 |
| Omeprazole | Omeprazole | 140 | 39 |
| Gabapentin | Gabapentin | 129 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 34 |
| Potassium Chloride | Potassium Chloride | 115 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 21 |
| Allopurinol | Allopurinol | 110 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 36 |
| Glimepiride | Glimepiride | 104 | 33 |
| Carvedilol | Carvedilol | 97 | 30 |
| Furosemide | Furosemide | 93 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 92 | 22 |
| Jardiance | Empagliflozin | 90 | 23 |
| Ezetimibe | Ezetimibe | 82 | 23 |
| Simvastatin | Simvastatin | 80 | 30 |
| Finasteride | Finasteride | 78 | 22 |
| Eliquis | Apixaban | 73 | 25 |
| Famotidine | Famotidine | 73 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 27 |
| Valsartan | Valsartan | 63 | 18 |
| Celecoxib | Celecoxib | 62 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 61 | 17 |
| Ozempic | Semaglutide | 61 | 17 |
| Alprazolam | Alprazolam | 60 | 17 |
| Trulicity | Dulaglutide | 60 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 15 |
| Metformin Hcl Er | Metformin Hcl | 58 | 18 |
| Trazodone Hcl | Trazodone Hcl | 58 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 55 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 14 |
| Synthroid | Levothyroxine Sodium | 49 | 14 |
| Farxiga | Dapagliflozin Propanediol | 47 | 14 |
| Benazepril Hcl | Benazepril Hcl | 46 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 43 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 15 |
| Atenolol | Atenolol | 40 | 13 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | 13 |
| Spironolactone | Spironolactone | 37 | 15 |
| Montelukast Sodium | Montelukast Sodium | 35 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 11 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Klor-Con 10 | Potassium Chloride | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Prednisone | Prednisone | 20 | 11 |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | 14 |
| Digoxin | Digoxin | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 16 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 15 | 13 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,694.20 · 55 records | Novo Nordisk Inc | Artis Q floor, BOTOX, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Fabhalta, JARDIANCE, Kerendia, Korlym, MAGNETOM Altea, MINIMED 780G, MOUNJARO, OTEZLA, Ozempic, PROLIA, REPATHA, Rybelsus, VALTOCO, Wegovy, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error